Del Zompo F, Crouchet E, Ostyn T, Nehme Z, Messé M, Juehling F, Désert R, Vieira AT, Moehlin J, Nakib D, Andrews T, Perciani C, Chung S, Bader G, McGilvray I, Caime C, Scaravaglio M, Carbone M, Invernizzi P, Yaqub S, Folseraas T, Karlsen TH, Shankar G, Primeaux M, Dhawan Pet al.(2025) Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis J Hepatol(in press) DOI 10.1016/j.jhep.2025.08.005, PubMed 40846184
Sudmann TM, Jørstad ØK(2025) På høy tid med individuell vurdering av kjøreevne Tidsskr Nor Laegeforen, 145(9) DOI 10.4045/tidsskr.25.0413, PubMed 40844342
Nilsen DWT, Leon De La Fuente R, Gallo P, Naesgaard P, Dib Ashur S, Michelsen AE, Aukrust P, Staines H, Ueland T(2025) Reply to: Letter to the editor: High admission levels of interleukin-1 receptor antagonist in acute myocardial infarction patients Int J Cardiol, 133807(in press) DOI 10.1016/j.ijcard.2025.133807, PubMed 40840598
Dwt N, Leon De La Fuente R, Gallo P, Naesgaard P, Dib Ashur S, Michelsen AE, Aukrust P, Staines H, Ueland T(2025) Reply to: Letter regarding the study by Nilsen et al. on IL-1RA and 5-Year Mortality Risk: Redefining the Threshold for high admission levels of IL-1RA Int J Cardiol, 133806(in press) DOI 10.1016/j.ijcard.2025.133806, PubMed 40840594
